Coalition for Epidemic Preparedness Innovation

Coalition for Epidemic Preparedness Innovation (2017, Oslo, 11+Staff;

Sponsored by Wellcome Trust, Gates Foundation, World Economic Forum and governments of Norway and India to improve diagnostics, vaccines, therapeutics; focus on priority pathogens.  An example of CEPI’s work: assessed 224 vaccine candidates from preclinical through to phase 2 for 11 priority epidemic infectious diseases. The cost of progressing at least one vaccine through to the end of phase 2a for each of the 11 diseases would be a minimum of $2.8-$3.7 billion. The global cost of a moderately severe to severe pandemic is thought to be as much as $570 billion.


  • Priority Diseases
    • MERS-CoV
    • Lassa
    • Nipah
    • Disease X
    • Rift Valley Fever
    • Chikunguya
  • Vaccine Science
    • Biological Standards, Assays and Animal models
    • Vaccine pipeline data
    • Researching emerging infectious diseases


  • News on epidemic outbreaks
  • Blog
  • Twitter

Leadership: Richard Hatchett, CEO

Budget: CEPI has secured $750 million toward its $1billion funding target, with multi-year funding from Norway, Germany, Japan, Canada, Australia, the Bill & Melinda Gates Foundation, and Wellcome.

Scroll Up
Wordpress Social Share Plugin powered by Ultimatelysocial